Login
Companies $STXS
$0.80 +$0.00 (0.0%) After hours
Stereotaxis, Inc. logo

Stereotaxis, Inc.

stereotaxis.com

What Do They Do?

Sells robotic systems, catheters and information systems for hospitals and physicians performing heart and other blood-vessel procedures.

How Do They Make Money?

Most revenue comes from disposables, service and accessories; hospitals buy disposable devices for procedures and pay recurring service and software charges, with disposable sales tied to shipment or delivery. They also pay upfront for systems and installation, with system sales tied to acceptance of delivery or installation.

revenue
SegmentShareRevenue
Systems
Sold outright

32%
FY2022: 24%
Disposables Service and Accessories
68%
FY2022: 76%

Who Are Their Customers?

Hospitals purchase systems directly or through distributors; Stereotaxis also markets its products through sales agents, while third parties sometimes handle support as the customer's single point of contact.

Do Revenues Turn Into Profits?

No. It lost $21.6M in FY2025.

Operating income, FY2025
−68% of revenue
▲ +11% (Loss) vs FY2024 (−$24.7M, −92%)
Net income, FY2025
−67% of revenue
▲ +10% (Loss) vs FY2024 (−$24M, −89%)
Free cash flow, FY2025
−43% of revenue
▼ −62% (Loss) vs FY2024 (−$8.5M, −32%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +20%
vs $7.5M in Q3 FY2025
Net income
▼ 0% (Loss)
vs −$6.5M in Q3 FY2025
Disposables Service and Accessories share of revenue vs 75.1% in Q3 FY2025
  • Nov 9, 2026 Sets quarterly expense outlook and cash-flow profitability goal Adjusted operating expenses are expected to approximate $8 million per quarter going forward, with a path to cash-flow profitability within the next year.
  • Jul 7, 2026 Completes acquisition of Robocath Robocath develops robotic technologies for interventional cardiology and neurointerventions.

Flat. Revenue was $32.4M in FY2025, about the same as the $35M of FY2021.

Expanded product range The older report describes Genesis RMN and Odyssey as primary products and separately lists an integrated x-ray system; the latest lists GenesisX, Synchrony and SynX, and branded interventional devices including Map-iT, MAGiC and EMAGIN.

Revenue over time
Systems Disposables Service and Accessories Sublease
$50M$25M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support